Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments

Dermatology

Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Lirentelimab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Treatments. 

This study is recruiting participants who are at least 18 years old. 

Sponsor(s)
Allakos
Principal Investigator(s)
Dr. Jonathan I Silverberg
Contact Phone Number
(202) 677-6160
Request Information
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.